Stoke Therapeutics, Inc. (STOK)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$29.81-0.60%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · STOK
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Complete enrollment of 162 patients in Phase 3 EMPEROR study and initiate rolling NDA submission in Q1 2027 with data readout expected in Q3 2027.
Stated as a priority in 3 quarters including 2026-Q1 and 2026-Q2. Enrollment increased from approximately 150 patients in 2026-Q1 to 162 patients by 2026-Q2. Management plans to initiate rolling NDA submission in Q1 2027 with data readout expected in Q3 2027. The trajectory is delivering as enrollment completed and regulatory milestones are on track.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Enrollment of 162 patients complete with data readout anticipated in Q3 2027; rolling NDA submission planned to initiate in Q1 2027.”
“Enrollment of approximately 150 patients expected to complete in June 2026 to support data readout in mid-2027; rolling NDA submission planned to initiate in Q1 2027.”
Maintain strong financial position with cash and marketable securities expected to fund operations through potential U.S. commercialization of zorevunersen in early 2028.
Stated in 3 quarters including 2025-Q4 through 2026-Q2. Cash and equivalents increased slightly from $411 million in 2026-Q1 to $420 million in 2026-Q2. Management expects these funds to support operations through potential commercialization in early 2028. The trajectory is delivering with a stable strong cash position.
“Approximately $420 million in cash and equivalents expected to fund operations through potential U.S. commercialization in early 2028.”
“Had $411 million in cash, cash equivalents and marketable securities expected to fund operations into 2028.”
“Funds, combined with eligible proceeds from Biogen collaboration, anticipated to fund operations into 2028.”
Progress clinical development of STK-002 for ADOA and lead optimization for SYNGAP1-related disorders with data anticipated in 2027.
Stated in 2 quarters including 2026-Q1 and 2026-Q2. Clinical development of STK-002 is progressing with dose escalation ongoing and initial data expected in H1 2027. Lead optimization for SYNGAP1 is underway. The trajectory shows active advancement of pipeline beyond zorevunersen.
“Dose escalation continuing in Phase 1 OSPREY study of STK-002; initial data anticipated in first half of 2027; lead optimization underway for SYNGAP1.”
“First patient dosed in Phase 1 OSPREY study of STK-002; lead optimization underway to identify clinical candidate for SYNGAP1 in 2026.”
Enhance commercial readiness and build organizational capabilities to support potential U.S. launch of zorevunersen by early 2028.
Stated in 2 quarters including 2026-Q1 and 2026-Q2. Management emphasizes building commercial capabilities and organizational growth to support a potential U.S. launch by early 2028. The trajectory is consistent with preparatory activities ahead of commercialization.
“Continue to enhance commercial capabilities to support potential U.S. launch of zorevunersen by early 2028.”
“Focus turns increasingly to commercial preparedness and bringing zorevunersen to patients supported by strong financial position.”
Expand corporate headquarters and laboratory space with new lease to support growth.
Over the trailing year it converted 2.73x of net income into operating cash flow. Historically, Health Care names rated robust grew net income 55% of the time over the next year (vs 45% for the rest of the cohort, n=2490).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
11 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.